Related Experiment Video

Updated: Sep 10, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

596

Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer

Zhiyan Li1, Xiang Jia1, Ian Timothy Sembiring Meliala2

  • 1College of Pharmacy and Biological Engineering, Chongqing University of Technology, Chongqing 400054, China.

Biomolecules
|August 28, 2025
PubMed

Insights

Yin Yang 1 (YY1) drives tumor drug resistance through multiple mechanisms. Inhibiting YY1 can reverse resistance and restore treatment sensitivity, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Tumor drug resistance is a significant barrier to effective cancer treatment.
  • Yin Yang 1 (YY1) is an oncogene implicated in various tumor processes, including drug resistance.
  • YY1's role in mediating resistance involves complex molecular mechanisms and tumor microenvironment interactions.

Purpose of the Study:

  • To review the pivotal role of Yin Yang 1 (YY1) in mediating tumor drug resistance.
  • To elucidate the molecular mechanisms by which YY1 contributes to therapeutic resistance.
  • To discuss the clinical relevance and therapeutic potential of targeting YY1 to overcome drug resistance.

Main Methods:

  • Literature review of studies investigating Yin Yang 1 (YY1) in cancer drug resistance.
  • Analysis of molecular pathways and mechanisms driven by YY1 in tumor cells and the microenvironment.
  • Evaluation of preclinical and clinical data on YY1 inhibition strategies.

Main Results:

  • YY1 overexpression is linked to resistance across multiple tumor types and treatment modalities.
  • YY1 promotes resistance via mechanisms including drug efflux, cancer stemness, DNA repair, and epithelial-mesenchymal transition.
  • Inhibition of YY1 has shown potential to reverse drug resistance and enhance therapeutic sensitivity.

Conclusions:

  • Yin Yang 1 (YY1) is a critical regulator of tumor drug resistance.
  • Targeting YY1, especially in combination with existing anti-tumor agents, presents a promising strategy to overcome resistance.
  • Further translational research is needed to advance YY1-targeted therapies into clinical practice.
Keywords:
Yin Yang 1cancer treatmentcombination therapydrug resistancemolecular mechanisms

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
259